BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20651074)

  • 1. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
    Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
    Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and lenalidomide in primary myelofibrosis.
    Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
    Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
    Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
    Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
    Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
    Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
    Nijhof IS; Franssen LE; Levin MD; Bos GMJ; Broijl A; Klein SK; Koene HR; Bloem AC; Beeker A; Faber LM; van der Spek E; Ypma PF; Raymakers R; van Spronsen DJ; Westerweel PE; Oostvogels R; van Velzen J; van Kessel B; Mutis T; Sonneveld P; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Blood; 2016 Nov; 128(19):2297-2306. PubMed ID: 27647864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
    Stewart AK; Jacobus S; Fonseca R; Weiss M; Callander NS; Chanan-Khan AA; Rajkumar SV
    Blood; 2015 Sep; 126(11):1294-301. PubMed ID: 26157076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
    Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
    Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
    Fan WJ; Wu T; Chen JW; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
    Livun A; Newberry KJ; Manshouri T; Kusec R; Verstovsek S
    Anticancer Res; 2015 Oct; 35(10):5219-23. PubMed ID: 26408680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
    Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
    Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.